WO2006010077A3 - Prodrugs of lonidamine and lonidamine analogs - Google Patents
Prodrugs of lonidamine and lonidamine analogs Download PDFInfo
- Publication number
- WO2006010077A3 WO2006010077A3 PCT/US2005/024434 US2005024434W WO2006010077A3 WO 2006010077 A3 WO2006010077 A3 WO 2006010077A3 US 2005024434 W US2005024434 W US 2005024434W WO 2006010077 A3 WO2006010077 A3 WO 2006010077A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lonidamine
- prodrugs
- analogs
- methods
- well
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides prodrugs of lonidamine and lonidamine analogs as well as methods of using such prodrugs.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58693404P | 2004-07-08 | 2004-07-08 | |
| US60/586,934 | 2004-07-08 | ||
| US62450504P | 2004-11-01 | 2004-11-01 | |
| US60/624,505 | 2004-11-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2006010077A2 WO2006010077A2 (en) | 2006-01-26 |
| WO2006010077A3 true WO2006010077A3 (en) | 2006-08-31 |
Family
ID=35785776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2005/024434 Ceased WO2006010077A2 (en) | 2004-07-08 | 2005-07-08 | Prodrugs of lonidamine and lonidamine analogs |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2006010077A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015002996A1 (en) * | 2013-07-01 | 2015-01-08 | University Of Georgia Research Foundation, Inc. | Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy |
| EP3564214B1 (en) | 2018-05-04 | 2024-07-03 | Universita' Degli Studi G. D'annunzio Chieti - Pescara | Indazole derivatives as modulators of the cannabinoid system |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3895026A (en) * | 1972-02-29 | 1975-07-15 | Acraf | Substituted 1-benzyl-1h-indazole-3-carboxylic acids and derivatives thereof |
| US5260327A (en) * | 1985-10-02 | 1993-11-09 | Sloan-Kettering Institute For Cancer Research | Methods for inhibiting the proliferation of brain and hepatic metastases by using lonidamine |
-
2005
- 2005-07-08 WO PCT/US2005/024434 patent/WO2006010077A2/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3895026A (en) * | 1972-02-29 | 1975-07-15 | Acraf | Substituted 1-benzyl-1h-indazole-3-carboxylic acids and derivatives thereof |
| US5260327A (en) * | 1985-10-02 | 1993-11-09 | Sloan-Kettering Institute For Cancer Research | Methods for inhibiting the proliferation of brain and hepatic metastases by using lonidamine |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006010077A2 (en) | 2006-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007133290A3 (en) | Anti-ox40l antibodies and methods using same | |
| MX286273B (en) | Compositions and methods for inhibition of the jak pathway. | |
| WO2006023651A3 (en) | Extended treatment of multiple sclerosis | |
| ZA200605348B (en) | Solid forms of anti-EGFR-antibodies | |
| WO2006119329A3 (en) | Compositions and methods for the treatment of neurodegenerative diseases | |
| WO2006124713A3 (en) | 4-biarylyl-1-phenylazetidin-2-ones | |
| WO2007130697A3 (en) | Anti-ephb4 antibodies and methods using same | |
| EP1641437A4 (en) | The solid dispersion of tacrolimus | |
| WO2007127506A8 (en) | Anti-ephrinb2 antibodies and methods using same | |
| TW200613308A (en) | Cyclobutanetetracarboxylate compound and preparation method thereof | |
| ZA200805711B (en) | Solid biocidal compositions and methods of using the same | |
| PL1711473T3 (en) | Substituted n-cyclohexylimidazolinones having an mch-modulatory effect | |
| WO2008069976A3 (en) | Compounds and methods for enzyme-mediated tumor imaging and therapy | |
| WO2006015191A3 (en) | Multicyclic lonidamine analogs | |
| WO2006081337A3 (en) | Erastin analogues and their uses for killing cancer cells | |
| WO2007117704A3 (en) | Pure isomers of tritoqualine | |
| WO2007022321A3 (en) | Substituted indoles and use thereof | |
| WO2006010077A3 (en) | Prodrugs of lonidamine and lonidamine analogs | |
| WO2006095173A3 (en) | Medical uses of 39-desmethoxyrapamycin and analogues thereof | |
| GB0313630D0 (en) | Compositions for the enhanced treatment of depression | |
| WO2007064997A3 (en) | Compounds and methods for inhibiting apoptosis | |
| WO2006031799A3 (en) | Compositions comprising ubiquinones | |
| WO2006116687A3 (en) | Nanoassays | |
| WO2006064517A3 (en) | Methods for the purification of 20(s)-camptothecin | |
| GB2418723B (en) | Description of the office mouse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| 122 | Ep: pct application non-entry in european phase |